Company news

Nippon Shinyaku Co., Ltd. news in 2026

Nippon Shinyaku Co., Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Nippon Shinyaku Enters into Exclusive Sublicense Agreement with Tanabe Pharma to Commercialize loncastuximab tesirine-lpyl (MT-2111) for Relapsed or Refractory Diffuse Large B-cell Lymphoma in Japan

October 29, 2026

SAKIGAKE Pharmaceutical Product (Pioneering Drug) Designation Granted to NS-035 for the Treatment of Fukuyama Congenital Muscular Dystrophy

August 26, 2026

Notice Regarding Completion of Disposal of Treasury Stock as Restricted Stock Compensation

August 19, 2026

Regarding the U.S. Litigation Concerning CAP-1002 (deramiocel) – U.S. Court Denies Motion for Preliminary Injunction and Refers Dispute to Arbitration

August 9, 2026

Consolidated Financial Results for the First Quarter of Fiscal Year 2026(IFRS)

August 5, 2026

Exercises Option Rights for Commercialization of AB2 Bio’s Tadekinig alfa in the U.S.

July 30, 2026

Nippon Shinyaku Enters into an Exclusive License Agreement for the Development, Manufacturing, and Commercialization of NS-025 Worldwide

July 22, 2026

Notice Regarding Disposal of Treasury Stock as Restricted Stock Compensation

July 21, 2026

Nippon Shinyaku and Elixirgen Enter into an Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

June 26, 2026

Orphan Drug Designation granted to NS-035 for the Treatment of Fukuyama congenital muscular dystrophy in Japan

June 23, 2026

Nippon Shinyaku Enters into a Sponsored Research Agreement with Boston Children’s Hospital

June 23, 2026

Outline of Consolidated Financial Results for the Year Ended March 31, 2026

May 14, 2026

Announcement of a Lawsuit Filed against Nippon Shinyaku

May 8, 2026

Nippon Shinyaku Enters Collaboration with xFOREST Therapeutics on Drug Discovery Research Targeting RNA Structures

April 10, 2026

Nippon Shinyaku start co-promotion activities of OPSUMIT® Pediatric Dispersible Tablets 1mg and 2.5mg for the Treatment of Pulmonary Arterial Hypertension

March 17, 2026

Transfer of Marketing Authorization for Epileptic Seizures treatment FINTEPLA® Oral Solution 2.2 mg/mL

February 23, 2026

Notice Regarding Executive Personnel Changes

February 9, 2026

Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2025

February 8, 2026

Decks in 2026